목적: 고령의 퇴행성 슬관절 골관절염 환자를 대상으로 국내 건강보험 심사평가원(Health Insurance Review & Assessment Service, HIRA) 기준과 세계보건기구 fracture risk assessment tool (FRAX<SUP>®</SUP>, http://www.shef.ac.uk/FRAX/)에서의 골절 확률을 바탕으로 한 골다공증 치료 대상의 차이를 비교, 평가하고자 한다. 대상 및 방법: 2010년 6월부터 2011년 3월까지 퇴행성 슬관절 골관절염으로 인공관절 전치환술 시행예정인 65세 이상의 환자를 조사하였다. 치료 대상은 국내 HIRA 기준, T 점수 -2.5 이하이거나 FRAX<SUP>®</SUP> 기준의 10년 주요 골다공증 골절 확률 20% 및 대퇴골절 확률 3% 이상으로 정하였다. 결과: 929명 환자 중 골다공증 치료 대상은 국내 HIRA 기준 562명(60.5%), FRAX<SUP>®</SUP> 기준 372명(40.0%)이었다. 두 기준 모두 치료 대상으로 만족하는 경우는 339명(36.5%)으로, 비치료 대상 334명(36.0%)을 포함하여 673명(72.4%)의 낮은 진단 일치도를 보였다(κ값=0.471). 골감소증 319명 환자 중 33명(10.3%)은 FRAX<SUP>®</SUP> 기준의 치료 대상으로 분류되었다. 결론: 골다공증을 진단하고 치료함에 있어 국내 HIRA 기준에 FRAX<SUP>®</SUP>를 반영한 적정 치료 지침에 대한 보완이 필요하다.
Purpose: To compare and evaluate any differences in the osteoporosis treatments of elderly patients with degenerative osteoarthritis of the knee joints, in accordance with the Korean Health Insurance Review & Assessment Service (HIRA) criteria versus the World Health Organization (WHO) fracture risk assessment tool (FRAX<SUP>®</SUP>, http://www.shef.ac.uk/FRAX/) criteria, which is a fracture risk assessment tool developed by the WHO. Materials and Methods: From June 2010 to March 2011, we investigated and screened the target populations of osteoporosis treatments among 65-year-old or older patients with degenerative osteoarthritis of the knee joints who scheduled to undergo elective total knee arthroplasty. They were classified in the treatment group only if they met either the HIRA criterion, defined as having a T score of ≤?2.5 points, or the FRAX<SUP>®</SUP> criteria, defined as the 10-year probability of a major osteoporotic fracture and hip fracture of ≥20% or ≥3%, respectively. Results: Of a total of 929 patients, the number of patients included in the treatment group as screened according to the HIRA or FRAX<SUP>®</SUP> criteria was 562 (60.5%) and 372 (40.0%), respectively. The number of patients who met both criteria was 339 (36.5%), and including 334 non-treated patients (36.0%), a total of 673 patients (72.4%) showed low diagnostic concordance (k=0.471). Of 319 patients diagnosing osteopenia, 33 (10.3%) patients were included in the treatment group according to the FRAX<SUP>®</SUP> criteria. Conclusion: A combination of the HIRA and FRAX<SUP>®</SUP> criteria is required to improve the current guidelines for osteoporosis treatment.